Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other financing activities (2020 - 2024)

Keros Therapeutics' Other financing activities history spans 4 years, with the latest figure at $130000.0 for Q3 2024.

  • For Q3 2024, Other financing activities rose 381.48% year-over-year to $130000.0; the TTM value through Dec 2025 reached $130000.0, down 41.96%, while the annual FY2024 figure was $171000.0, 81.91% up from the prior year.
  • Other financing activities reached $130000.0 in Q3 2024 per KROS's latest filing, up from $67000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $219000.0 in Q1 2020 to a low of $8000.0 in Q2 2020.
  • Average Other financing activities over 4 years is $106285.7, with a median of $100000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: tumbled 48.19% in 2021, then surged 381.48% in 2024.
  • A 4-year view of Other financing activities shows it stood at $193000.0 in 2020, then tumbled by 48.19% to $100000.0 in 2021, then tumbled by 33.0% to $67000.0 in 2023, then skyrocketed by 94.03% to $130000.0 in 2024.
  • Per Business Quant, the three most recent readings for KROS's Other financing activities are $130000.0 (Q3 2024), $67000.0 (Q4 2023), and $27000.0 (Q3 2023).